Breaking News

0 320
Donald Trump

The market has been up significantly since Trump won the election and the S&P 500 Index is at a mind-boggling valuation. The S&P 500 Index’s market valuation reached over $20 trillion on February 13, 2017, and the market is at all-time highs. Now, this was primarily driven by Trump and his move to potentially cut taxes, and the POTUS has a ‘phenomenal’ tax announcement within the coming weeks. That’s great news for many companies, as they would be able to potentially increase their earnings, which could continue to fuel their stock prices. Trump’s tax plan isn’t his only proposed change that has been pushing the markets higher, there are some industries that have benefitted from the potential change in the political landscape.





Banking Industry

It goes without saying, many banks and financial services firms do not like the increased regulations due to the Dodd-Frank Act, which imposed some rules to protect investors after the financial crisis of 2008. Trump has been looking to decrease regulations in multiple industries, the financial services being one of them. This is music to financial services companies’ ears.

In early February 2017, Trump ordered a review of Dodd-Frank Act rules and aims to scale back many regulations, which would benefit the financials industry. However, Federal Reserve Chair Janet Yellen is largely against this move. When speaking on Trump’s comments on the Dodd-Frank Act, Yellen stated, “I see well-capitalized banks that are regarded as safe, strong and sound.”




According to trader Jason Bond, “Trump’s proposed corporate tax plan could help multiple industries increase their earnings. Moreover, the President’s potential move to decrease regulations and rollback some expensive regulations could continue to push financials. The Financial Select Sector SPDR Fund has already been up 10.10% over the past quarter and nearly 50% over the past year, and it could continue higher.”

Now, Gold Sachs climbed to a record high, after market participants placed bets on the stock because of President Trump’s potential changes, which would increase trading activity and deal making. Moreover, the potential tax cuts and removal of some costly regulations removal should continue to push the stock higher. This theme is inherent across many financial services firms, and market participants may want to keep an eye on stocks in this sector.

Energy Industry

President Trump is also looking to increase activity in the traditional energy industry. Trump has indicated that he does not believe in global warming and even stated it was invented by the Chinese. Now, whether you believe in global warming or not, Trump’s statements have had a large impact on the energy industry. Trump has stated environmental regulations are “out of control”, and the President has already moved to rollback some environmental regulations, which could be a sign that he’s supporting the traditional energy industry.

Now, Trump recently removed the rule for anti-corruption in the energy industry, using the Congressional Review Act to kill the rule that required oil, gas and mining companies listed on U.S. stock exchanges to disclose the amount they pay foreign governments. With this deregulation, there could be increased activity in the industry, potentially increasing profits for energy companies.

The Bottom Line

The Trump trades are still on the table, and the banking and traditional energy industries could still benefit from potential deregulations and tax cuts. However, the financial services and energy industries aren’t the only ones that could rise under the Trump administration. That being said, market participants may want to keep an eye out on these two industries for now since they’ve been showing strong performance so far since Trump’s election win.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 788
Cempra Inc CEMP Stock News

Cempra Inc (NASDAQ: CEMP)

Cempra is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading with impressive gains. Since the bell, we’ve seen a bit of movement in both directions, but the stock is still holding onto the profits. Below, we’ll talk about what we’re seeing from CEMP, why, and what we’ll be watching for ahead.





What We’re Seeing From CEMP

As mentioned above, Cempra is having an incredible time in today’s trading session. When the session started, the stock had already reached dramatic gains. Since the open, we’ve seen some upward and some downward movement, but one thing is clear; the stock is likely to close with impressive gains. At the moment (9:54), CEMP is trading at $4.36 per share after a gain of $1.21 per share (38.41%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on CEMP. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the upward movement. It didn’t take long to dig up the story. It seems as though today’s gains are the result of positive data released from a Phase 3 study.




Early this morning, Cempra released clinical data from its phase 3 study of oral fusidic acid. During the study, 716 patients were treated, and the results met the primary endpoint. In the treated patient population, the treatment proved non-inferiority of oral fusidic acid compared to oral linezolid for early clinical response in the treated patient population. In a statement, David Oldach, M.D., CMO at CEMP, had the following to offer:

We are excited that the results of this Phase 3 study with fusidic acid confirm the results of our phase 2 study and are consistent with the more than 40 years of experience that the product has accumulated outside of the United States.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CEMP. In particular, we’ll be watching the company as it takes fusidic acid to the next level, pushing for FDA approval. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 536
IntelliPharmaCeutics International Inc. IPCI Stock News

IntelliPharmaCeutics International Inc. (NASDAQ: IPCI)

IntelliPharmaCeutics International is likely to have an incredibly strong day in the market today. That’s because the stock is skyrocketing in the pre-market, following news of FDA approval. Below, we’ll talk about what we’re seeing from IPCI, the FDA approval, and what we’ll be watching for ahead.





What We’re Seeing From IPCI

As mentioned above, IntelliPharmaCeutics International is having an incredibly strong time in the pre-market hours this morning. When news broke earlier of FDA approval, the stock skyrocketed upward and is going to be starting the day well into the green. At the moment (9:24), IPCI is trading at $2.70 per share after a gain of $0.55 per share (25.58%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the run upward on IPCI. As soon as we received the alert, the CNA Finance team started working to see why the stock was making a mad dash for the top. It didn’t take long to uncover the story. The gains are ultimately the result of an FDA approval.




Early this morning, IntelliPharmaCeutics International announced that it has received Food and Drug Administration approval to market metformin hydrochloride extended release tablets in both 500 mg and 750 mg strengths. This product is the generic equivalent to Glucophage(R) XR, which is currently being sold by Bristol-Myers Squibb. In a statement, Dr. Isa Odidi, CEO and Co-Founder of IPCI, had the following to offer:

FDA approval for our application for a generic version of Glucophage(R) XR products provides further indication that the FDA is making progress to clear its backlog of ANDA drug candidates under review, and further validation of our core drug development and regulatory capability. We are encouraged that some of the Company’s other 8 ANDA candidates may be accorded further attention soon. We are actively evaluating options to realize commercial returns from this new approval.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on IPCI. In particular, we’re interested in learning more about the company’s plans for commercialization of this newly-approved generic treatment. We’re also interested in the several ANDA’s that the company has filed and how those will turn out down the road. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 610
Actinium Pharmaceuticals Inc ATNM Stock News

Actinium Pharmaceuticals Inc (NYSEMKT: ATNM)

Actinium Pharmaceuticals (ATNM) is continuing upon its aggressive informational campaign to tout the potential benefits of Iomab-B, ATNM’s lead clinical compound. Iomab-B is currently being studied in a 150-patient, multicenter phase III pivotal trial, in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. The meetings are scheduled to take place on February 22-26, 2017 in Orlando , Florida.





Presenting At BMT Tandem Meetings

The BMT Tandem Meetings will provide ATNM with a targeted audience that host worldwide experts in blood and marrow transplant care, clinical investigation and laboratory research. The annual event is one of the largest gatherings of industry experts in North America, with over 3000 transplant physicians from over 500 transplant centers expected to attend.

Specifically, the BMT Tandem Meetings include an extensive scientific program that addresses state-of-the-art issues in bone marrow transplant and procedure. Attendees at this event include investigators, clinicians, laboratory technicians, clinical research professionals, and wide inclusion of other field specialists seeking to benefit from the meetings’ hematopoietic cell transplantation focused program.




For its part, ATNM will be represented by an encompassing team of professionals, comprised of clinical, medical, business development, and marketing personnel, with a coordinated plan to host a full agenda of activities related to ATNM’s advisory board meetings. ATNM will also command a booth presence for Iomab-B and its on-going SIERRA trial, with the booth providing advantages and aid in facilitating meetings with potential partners and collaborators.

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals believes that attendance at the BMT Tandem Meeting will prove beneficial, saying, “Our lead drug candidate, Iomab-B, is being developed to prepare patients for a bone marrow transplant with the hopes of enabling an increased number of elderly patients with relapsed or refractory leukemia to obtain a transplant compared to current salvage chemotherapy conditioning. Given our focus on transplant, the BMT Tandem meetings are a major event for us, which give us great insights into this exciting field while motivating us to all we can to improve outcomes for patients in need.”

ATNM And Iomab-B

Recently featured on CNA Finance, Iomab-B is Actinium’s lead product candidate, which is currently being studied in a 150-patient, multicenter pivotal Phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.

ATNM has additional pipeline strength. The company’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.

Stay focused to CNA Finance for additional breaking news coverage and clinical developments from ATNM.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Northern Dynasty Minerals Ltd NAK Stock News

Northern Dynasty Minerals Ltd (NYSEMKT: NAK)

Northern Dynasty Minerals is having an incredibly strong day in the market today. After starting the day off well into the green, the stock continued on a relatively strong upward trend through most of the morning. While we have seen some slight downward movement more recently, chances are that the stock will close well into the green. Below, we’ll talk about what we’re seeing from NAK, why, and what we’ll be watching for ahead.





What We’re Seeing From NAK

As mentioned above, Northern Dynasty Minerals is having an incredibly strong trading session in the market today. At the opening bell, the stock was already trading slightly in the green. Since then, we’ve seen more gains bringing it to highs and slight declines since. At the moment (11:18), NAK is trading at $1.74 per share after a gain of $0.34 per share (24.29%) thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on NAK. When we received the alert, the CNA Finance team started digging to see why the stock was making a run for the top. It didn’t take long to dig up the story. The gains are ultimately the result of news surrounding the Pebble Project.




In the announcement, investors learned that the US House Committee on Science, Space, and Technology has called on the new Administrator of the US EPA to rescind the federal agency’s 2014 regulatory action of the Clean Water Act. If the move is rescinded, the Alaskan Pebble Project will be a major beneficiary.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NAK. In particular, we’ll be watching for further news surrounding the Pebble Project and how the developments will affect the stock moving forward. We’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 618
Athersys, Inc. ATHX Stock News

Athersys, Inc. (NASDAQ: ATHX)

Athersys is having an incredibly strong day in the market today. After starting the day off in the red, the stock started moving upward as soon as the opening bell rang. Since then, we’ve seen a continuation of strong movement, bringing the stock well into the green. Below, we’ll talk about what we’re seeing from ATHX, why, and what we’ll be watching for ahead.





What We’re Seeing From ATHX

As mentioned above, Athersys is having a great day in the market today. At the opening bell, the stock was trading well into the red. However, that didn’t last long. As soon as trading started for the day, the stock started making a strong push toward the top that hasn’t stopped yet. Currently (10:49), ATHX is trading at $1.16 per share after a gain of $0.03 per share or 2.65% thus far today.

Why The Stock Is Running Upward

As is nearly always the case, our friends at Trade Ideas were the first to send the alert that ATHX was making a run for the top. As soon as we received it, the CNA Finance team started to work to see exactly what was causing the movement. It didn’t take long to dig up the story. Ultimately, the gains are being caused by an announcement the company made through a press release early this morning.




In the press release, Athersys announced a coming presentation that is centered around its MultiStem(R) cell therapy treatment for ischemic stroke. The presentation will be given at the International Stroke Conference 2017 this week. In a statement, Dr. Houkin, the presenter, had the following to offer…

We are very excited to be commencing this clinical trial at Hokkaido University Hospital and then at other leading stroke centers across Japan… The need for safe, effective and clinically-preactical treatments for ischemic stroke patients has never been greater. Based on the clinical results from the recently completed MASTERS-1 Phase II clinical study, many believe that innovative treatments like MultiStem cell therapy hold great promise for treating the devastating effects of a stroke and helping patients recover more efficiently. Given the rapidly expanding aging population both in Japan and globally, safe and effective treatments that can reach a greater number of stroke victims could make a significant difference for many patients and their families.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on ATHX. In particular, we’re interested in the presentation to come and the company’s ongoing work with MultiStem cell therapy. Nonetheless, we’ll keep a close eye on the stock and continue to bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1268
FireEye Inc FEYE Stock News

FireEye Inc (NASDAQ: FEYE)

FireEye is having an incredibly interesting day in the market today, to say the least. When the trading session opened for the day, the stock was already trading in the green. However, it quickly spiked downward to the red before recovering and doing it again. And then the stock started to spike upward in a big way minutes ago. Below, we’ll talk about what we’re seeing from FEYE, why, and what we’ll be watching for ahead.





What We’re Seeing From FEYE

As mentioned above, FireEye is having a great time in the market at the moment. At the open of the market, the stock was already trading well into the green. However, it quickly fell to the red before recovering and repeating. Nonetheless, that repetition seems to be over, as the stock is spiking upward at the moment. Currently (10:36), FEYE is trading at $11.58 per share after a gain of $0.35 per share (3.12%) thus far today.

Why The Stock Is Spiking Upward

As is usually the case, our partners at Trade Ideas were the first to alert us to the gains on FEYE. When we got the alert, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to dig up the story. The gains seem to be the result of a takeover offer that broke seconds before the run!

In a report on Zero Hedge, it was announced that FireEye has received a takeover offer. The offer came from LifeLock, and it was a pretty good one with a strong premium. In fact, LifeLock said that it is willing to pay $16 per share in a takeover of the company. If this deal goes through, it will return tremendous value to shareholders.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FEYE. In particular, we’re interested in learning whether or not the company will take the offer. After all, with such a strong premium, chances are high. Nonetheless, we’ll keep a close eye on the story and continue to bring you the news as it breaks!

Update 11:46 – FEYE is taking a dive as news broke that LifeLock had interest in the company months ago, but is no longer interested in the acquisition. At the moment, the stock is trading at $11.45 per share after a gain of $0.22 per share (1.96%) thus far today.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 486
Avadel Pharmaceuticals plc AVDL Stock News

Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Avadel Pharmaceuticals is having a strong start to the trading session this morning. At the opening bell, the stock was trading slightly green before dipping down. However, minutes ago, that changed as the stock started to spike upward in a big way. Below, we’ll talk about what we’re seeing from AVDL, why, and what we’ll be watching for ahead.





What We’re Seeing From AVDL

As mentioned above, Avadel Pharmaceuticals is having a relatively strong day in the market today. At the opening bell, the stock was trading slightly green before dipping down near the break even point. However, minutes ago, the stock started to spike upward. At the moment (10:18), AVDL is trading at $10.59 per share after a gain of $0.38 per share or 3.72% thus far today.

Why The Stock Is Spiking Upward

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on AVDL. Of course, the CNA Finance team went to work to dig up the story as soon as we received the alert. It didn’t take long to find it. The gains are ultimately the cause of a large stake purchase that investors were made aware of early this morning.




Early this morning, it was announced that Broadfin Capital made a large share purchase on Avadel Pharmaceuticals. In fact, the purchase amounted to a 10.7% stake in the company. Of course, this caused excitement among investors. After all, smart money follows smart money, and Broadfin Capital is definitely well known and great at what they do.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AVDL. In particular, we’re interested in seeing whether or not the large share purchase will equate to changes in the company. Nonetheless, we’ll keep a close eye on the stock and continue to bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 817
Navidea Biopharmaceuticals Inc NAVB Stock News

Navidea Biopharmaceuticals Inc (NYSEMKT: NAVB)

Navidea Biopharmaceuticals isn’t having the best of mornings in the market today. In fact, when the trading session opened for the day, the stock was already trading on losses. From there, the stock dove further down, and now we’re receiving word that it has been halted. Below, we’ll talk about what we’re seeing from NAVB, why, and what we’ll be watching for ahead.





What We’re Seeing From NAVB

As mentioned above, Navidea Biopharmaceuticals isn’t off to the best of days in the market today. Unfortunately, the stock was trading well into the red at the opening bell. From there, it continued to slide further and further down. That is, until the stock was halted minutes ago. The halt happened at 9:57 with NAVB trading at $0.44 per share after a loss of $0.02 per share (4.63%) thus far today.

What’s Going On With The Stock

As is almost always the case, our partners at Trade Ideas were the first to inform us of the halt on NAVB. As soon as the CNA Finance team received the alert, we started digging to see if we could uncover the news. In this particular case, we’re seeing no fundamental news, no rumors, and nothing that we can attribute the halt to.




There is one thing we do know however, and that is that Navidea Biopharmaceuticals has indeed been halted. At the end of the day, trading doesn’t stop mid-session unless something big is happening. So, we know that we’re going to see some big news surrounding the stock ahead.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NAVB. In particular, we’re interested in figuring out exactly why the stock was halted and what the reason means for the future of the company. We’ll be watching the news closely and bringing it to you as it breaks!

UPDATE 10:30: We have found the cause of the halt. CRG has been granted to the right to exercise its remedies provided in a loan agreement. As a result, CRG will sell shares of Macrophage Therapeutics, Inc., a subsidiary of NAVB.

UPDATE 10:34: NAVB reopens far higher. Currently the stock is trading at $0.64 per share after a gain of $0.18 per share (40.32%) thus far today.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 474
AVEO Pharmaceuticals, Inc. AVEO Stock News

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

AVEO Pharmaceuticals is having an interesting start to today’s trading session. At the opening bell, the stock was trading on incredibly strong gains. While the bell just rang about 10 minutes ago, the stock has been in the midst of a steep correction. Below, we’ll talk about what we’re seeing from AVEO, why, and what we’ll be watching for ahead.





What We’re Seeing From AVEO

As mentioned above, AVEO Pharmaceuticals is having an interesting start to today’s trading session. Although the stock was trading well in the green at the opening bell, since the bell, it has been headed downward. Nonetheless, the stock is still trading on relatively impressive gains. Currently (9:40), AVEO is trading at $0.82 per share after a gain of $0.05 per share or 5.87% thus far today.

Why The Stock Is Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on AVEO. As soon as we received the alert, the CNA Finance team started digging to see exactly why the stock was up. It didn’t take long to dig up the story. The gains are the result of an announcement made early this morning.




In a press release, AVEO announced that its pivotal, Phase 3 TIVO-3 trial has successfully completed the first safety review. The review was done by the Safety Monitoring Committee, which concluded that there were no safety concerns observed for tivozanib. As a result, the Committee recommended that the study replace the small number of patients who dropped out prior to treatment.

In a statement, Michael Needle, M.D., CMO at AVEO had the following to offer…

Tivozanib is a unique molecule in that its high selectivity for VEGF is designed to reduce off target toxicity, thereby increasing tolerability and its combinability with other agents, such as immunotherapies…. We are very pleased to see the pace at which TIVO-3 is enrolling, and that it has completed its first safety review. We look forward to the futility analysis around midyear, and to other potential achievements in our tivozanib clinical program, including the expected first patient treated in the tivozanib and Opdivo(R) combination study, TiNivo, in early march.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on AVEO. We’re most interested in watching the company’s ongoing work with tivozanib as this could prove to be a massively profitable treatment in the long run. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 814
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...